Can sound waves replace the scalpel for breast cancer?
NCT ID NCT01620359
First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time
Summary
Researchers are testing whether a device called ExAblate MRgFUS can safely and completely destroy small breast cancers using focused ultrasound waves guided by MRI. The trial enrolls women with a single invasive breast tumor smaller than 2 centimeters who are already scheduled for surgery. The goal is to see if this non-invasive approach can ablate the entire tumor plus a safety margin, and whether MRI can accurately confirm the destruction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ExAblate MRgFUS, a device that uses focused ultrasound waves guided by MRI to heat and destroy breast cancer tissue
- What this could lead to
- If successful, this could offer a non-surgical option for treating small breast cancers, potentially reducing the need for lumpectomy or mastectomy.
- What could go wrong
- This is an early-phase trial with only 14 participants, so results may not apply broadly. Risks include incomplete tumor destruction, skin burns, or damage to nearby tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
14 people
The number who actually took part.
- Started
-
Nov 2010
- Finished
-
Apr 2014
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Women age 18 years with invasive breast cancer 2. Patient with contrast-enhanced MR imaging confirming a single focal breast lesion less than 2 cm in diameter 3. Lesion clearly seen on contrast-enhanced MR and in a treatable location 4. Patient who is willing to undergo and be scheduled for sentinel lymph node biopsy 5. Patient scheduled and consented to surgical (lumpectomy or mastectomy) resection of the breast cancer 6. Patient with clinical Stage I disease: T1 M0 N0 7. Patient who signs an informed consent form for screening, SLNB, ablation, and follow-up visits. Exclusion Criteria: 1. Invasive lobular carcinoma; 2. DCIS without invasive components on core biopsy; 3. Tamoxifen, Aromatase Inhibitors, and Neoadjuvant chemotherapy within 30 days prior to ExAblate. 4. Prior XRT or ablative therapy to the target breast; 5. Patients currently receiving anticoagulation therapy within the previous 14 days; 6. Lesions difficult to target (\<1 cm from skin, nipple or the rib cage), as visualized on pre-therapy MRI; 7. Microcalcifications as the only sign of breast cancer on imaging studies; 8. Extensive intraductal components (EIC) on core biopsy. 9. Patients with breast implants; 10. Patients with prior surgical clips or other markers at the site of the breast tumor; 11. Patients with severe cerebrovascular disease (multiple CVA or CVA within 6 months); 12. hemolytic anemia (hematocrit \< 30); 13. Pregnant or lactating, post-partum women; 14. Patient overall health status of ASA \>2 15. Patient with active and ongoing infection at any body site; 16. Poor blood glucose control. 17. Severe hypertension 18. Patients with unstable cardiac status 19. Contraindication to MR or ExAblate ablation therapy 20. Patient with history of deep vein thrombosis 21. With history of pulmonary embolism; 22. Patient with sleep apnea; 23. Patient with airway problems; 24. Patient with severe claustrophobia; 25. Patient with non-MRI compatible implanted metal devices; 26. Patient with difficulty lying prone and still for up to 3 hours (180 minutes) in the MR unit; 27. Patient who cannot fit comfortably in the magnet or patients \>250 lbs; 28. Patient with prior reaction to contrast agent; 29. Patient with history of grand mal seizures; 30. Patient with severely impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73m2 and/or who is on dialysis;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Marienhospital
Bottrop, 46236, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?